Home
 
ASTRAGALUS



RESEARCH

Influence of astragalus injection on serum cytokines and lung function in acute exacerbation of chronic obstructive pulmonary disease

Source:
Xiong Suqiong, Guo Yaping, Xiong Xi. Influence of astragalus injection on serum cytokines and lung function in acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Xian Dai Yi Sheng. 2013, 51 (9): 43-45.

To observe the effect of astragalus injection on tumor necrosis factor-α (TNF-α), interleukin 8 (IL-8), interleukin 2 (IL-2) and lung function in acute chronic obstructive pulmonary disease (AECOPD) a total of 112 patients with AECOPD were randomly divided into the treatment group (56 cases) and control group (56 cases). The treatment group received 40 mL astragalus injection and 5% glucose 250 mL intravenous drip once a day at the base of conventional therapy, while the control group received conventional therapy only. The therapeutic course of both groups was 14 days. The clinical therapeutic effects of both groups were observed, the serum levels of TNF-α, IL-8, IL-2, the lung function and blood gas analysis index of both groups was measured before and after the treatment. The treatment groups effect rate was 94.64%, control group was 67.86%, which was statistically significant (P<0.05). In the comparison before and after treatment, the levels of TNF-α, IL-8 in both groups were decreased obviously (all P<0.01), while the levels of IL-2 were increased obviously in the two groups (all P <0.01) after the treatment, in the treatment group, the extent of change was significantly greater than that in the control group (all P<0.01). The lung function and blood gas analysis index of both groups were improved significantly, especially in the treatment group (all P<0.01). Astragalus injection may significantly decrease the serum level of TNF-α and IL-8, increase the level of IL-2, it may improve the lung function and the curative effect in the patients with AECOPD.



The impact of Astragalus injection on residual renal function in Hemodialysis patients

Source:
Qi Ying-hui, Qu xiao-lu, Tang Yong-hua, Dai Qin, ZHANG Shan-bao, Yao Chun-ying. The impact of Astragalus injection on residual renal function in Hemodialysis patients. Xin Yi Xue. 2013, (2): 105-107.

To observe the effect of astragalus injection on hemodialysis patient’s RRF (residual renal function, RRF), sixty hemodialysis patients with RRF of more than 2ml/min were randomly divided into astragalus injection treatment group and control group with normal saline. One hour ahead of hemodialysis accomplishment, the treatment group were given with astragalus injection for 30ml, and the control group with normal saline for 30ml. A follow-up of 6 months including data of daily urine output and RRF were compared. After 6 months of observation, the treatment group’s daily urine output and RRF have all reduced, the latter one with statistical differences (P<0.05) The control group’s daily urine output and RRF have all reduced, both with statistical differences (P<0.05). After 6 months, the treatment group’s RRF has reduced by (1.17 ±0.21) ml/ min, and control group’s by (1.64 ± 0.53) ml/min. The comparison between the two groups was statistically significant (P<0.01). After 6 months observation, the treatment groups daily urine output was reduced by (70 ± 31) ml, and control group’s by (155 ± 59) ml, the comparison between the two groups was statistically significant (P <0.01). Astragalus injection can delay the speed of daily urine output reduction and protect RRF to some extent.

 
CopyRight 2012 - ICOP